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Plasmodium falciparum Infection of Human Volunteers Activates
Monocytes and CD16 Dendritic Cells and Induces Upregulation
of CD16 and CD1c Expression
Anne C. Teirlinck,a* Meta Roestenberg,a* Else M. Bijker,a* Stephen L. Hoffman,b Robert W. Sauerwein,a Anja Scholzena
Radboud University Medical Center, Department of Medical Microbiology, Nijmegen, The Netherlandsa; Sanaria Inc., Rockville, Maryland, USAb
Antigen-presenting cells (APCs) are key players in the induction and regulation of immune responses. In Plasmodium falcipa-
rummalaria, determination of which cells and pathways are activated in the network of APCs remains elusive. We therefore in-
vestigated the effects of a controlled humanmalaria infection in healthy, malaria-naive volunteers on the subset composition
and activation status of dendritic cells (DCs) andmonocytes. While subsets of monocytes increased in frequency during blood-
stage infection, DC frequencies remained largely stable. Activationmarkers classically associated with peptide presentation to
and priming ofT cells, HLA-DR and CD86, were upregulated in monocytes and inflammatory CD16myeloid DCs (mDCs)
but not in the classical CD1c, BDCA2, or BDCA3 DC subsets. In addition, these activated APC subsets showed increased expres-
sion of CD1c, which is involved in glycolipid antigen presentation, and of the immune complex binding Fc receptor III (CD16).
Our data show that P. falciparum asexual parasites do not activate classical DC subsets but instead activate mainly monocytes
and inflammatory CD16mDCs and appear to prime alternative activation pathways via induction of CD16 and/or CD1c.
Changes in expression of these surface molecules might increase antigen capture and enhance glycolipid antigen presentation in
addition to the classical major histocompatibility complex class II (MHC-II) peptide presentation and thereby contribute to the
initiation of T-cell responses in malaria. (This study has been registered at Clinicaltrials.gov under registration no.
NCT01086917.)
Infection with the malaria parasite Plasmodium falciparumcauses severe morbidity and mortality worldwide, especially in
sub-Saharan Africa (1). Dendritic cells (DCs) are dedicated anti-
gen-presenting cells (APCs) that orchestrate the immune system
and are among the first immune cells to encounter the parasite
after its inoculation into the skin by infected mosquitoes. Differ-
ent DC subsets have been described, some being derived from or
related to monocytes. Myeloid DCs (mDCs) are defined by the
expression of CD1c (BDCA-1), CD141 (BDCA-3), or CD16 (Fc
receptor III), while the marker for plasmacytoid DCs (pDCs) is
CD303 (BDCA-2) (2–4).
Previous studies investigating the effect of P. falciparum expo-
sure on DCs have shown somewhat contradictory results. In gen-
eral, DC function is considered to be impaired during acute ma-
laria, leading to immune tolerance (5, 6), based on a variety of
definitions of impairment related to DC frequency (7), antigen
uptake (8), viability (8), major histocompatibility complex class II
(MHC-II) and costimulatory molecule expression (7, 9–11), and
cytokine production (10, 11). In murine models, cross-presenta-
tion (12) and the ability to form stable interactions with T cells
(13) were shown to be impaired in DCs that were exposed to P.
berghei or P. chabaudi. In in vitro experiments, the effects of P.
falciparum blood-stage parasites on DCs are dependent on the
parasite dose used (11, 14), while differential results in studies of
natural infections may be explained by ethnicity (15) and age
and/or previous exposure (7).
Of note, the vast majority of studies have focused on classical
DC subsets and classical markers of DC activation, while inflam-
matory mDCs expressing Fc receptor III (CD16) (3) during ma-
laria infection have to our knowledge been included in the analysis
of DC subsets in only two studies (15, 16). Moreover, we previ-
ously established that duringmalaria, monocytes and DC subsets,
in particular CD16 CD14 inflammatory DCs, increase surface
B-cell activating factor (BAFF) expression and thus might poten-
tially facilitate B-cell responses (17). Although BAFF production
alone cannot be used as a marker for normal APC function or
activation, this adds to the hypothesis that APCs are not impaired
by a malaria infection per se but might merely gain alternative
functions. In addition to HLA-peptide recognition, protection
against malaria is associated with T cells expressing invariant
T-cell receptors, which can be activated by lipid-presenting mol-
ecules of the CD1 family (18, 19). Antigen uptake for presentation
Received 10 April 2015 Returned for modification 11 May 2015
Accepted 3 July 2015
Accepted manuscript posted online 13 July 2015
Citation Teirlinck AC, Roestenberg M, Bijker EM, Hoffman SL, Sauerwein RW,
Scholzen A. 2015. Plasmodium falciparum infection of human volunteers activates
monocytes and CD16 dendritic cells and induces upregulation of CD16 and
CD1c expression. Infect Immun 83:3732–3739. doi:10.1128/IAI.00473-15.
Editor: J. H. Adams
Address correspondence to Robert W. Sauerwein,
robert.sauerwein@radboudumc.nl, or Anja Scholzen,
anja.scholzen@radboudumc.nl.
* Present address: Anne C. Teirlinck, Centre for Infectious Disease Control, National
Institute for Public Health and the Environment (RIVM), Bilthoven, The
Netherlands; Meta Roestenberg, Department of Parasitology and Infectious
Diseases, Leiden University Medical Center, Leiden, The Netherlands; Else M. Bijker,
Department of Pediatrics, Canisius-Wilhelmina Hospital, Nijmegen, The
Netherlands.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/IAI.00473-15.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
doi:10.1128/IAI.00473-15
3732 iai.asm.org September 2015 Volume 83 Number 9Infection and Immunity
 o
n
 February 28, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://iai.asm
.org/
D
ow
nloaded from
 
is further mediated not only by endocytosis, as examined previ-
ously (8, 16), but also, for instance, by phagocytosis of immune
complex-associated antigens, which can be facilitated by the
FcIII receptor CD16 (20).
Here, we took advantage of the controlled human malaria in-
fection (CHMI) model, which provides an ideal condition to
study human immune cells after a first in vivo exposure to P.
falciparum at defined time points postinfection, to investigate par-
asite-mediated classical activation as well as potential changes in
CD1c and CD16 expression across DC and monocyte subsets in
human volunteers.
MATERIALS AND METHODS
Study subjects and controlled humanmalaria infection. Eighteen adult
malaria-naive Dutch volunteers were exposed to a CHMI at the Radboud
UniversityMedical Center (21). This phase I clinical trial was approved by
the Central Committee for Research Involving Human Subjects of The
Netherlands (CCMO NL31858.091.10) and has been registered at Clini-
caltrials.gov (NCT01086917). All volunteers provided written informed
consent. Infection was initiated by intradermal injection of 2,500, 10,000,
or 25,000 (n 6 per group) cryopreservedP. falciparumNF54 sporozoites
(PfSPZ Challenge) (21). Volunteers were monitored daily for symptoms
and signs of infection and hematological and biochemical parameters
during outpatient clinical visits beginning 5 days after inoculation of Pf-
SPZ Challenge. As soon as parasites were detected by microscopic exam-
ination of thick blood smears (TS), volunteers were treated with atova-
quone and proguanil (1,000 and 400 mg per day, respectively) for 3 days.
Cure was confirmed by results showing two consecutive parasite-negative
blood slides. Volunteers who did not develop parasitemia by day 21 after
challenge were presumptively treated with the same regimen. Fifteen vol-
unteers developed TS-detectable parasitemia. Neither the prepatent pe-
riod results determined by quantitative PCR nor the TS or peak parasite
densities differed between the three groups. Therefore, all TS-positive
(TS) volunteerswere analyzed as one group. Three volunteers remaining
TS after CHMI were analyzed in parallel. Those volunteers displayed no
changes inAPC subset frequency or activationmarker expression at any of
the time points analyzed (see Fig. S1 in the supplemental material).
PBMC isolation, cryopreservation, and staining. Peripheral blood
mononuclear cells (PBMCs) were collected the day before challenge in-
fection (C1), during liver-stage infection (C5) and early blood-stage
infection (C7 andC9), at the time of thick-smear positivity just prior
to drug treatment (day of treatment [DT]), 3 days after the day of treat-
ment (DT 3), and after convalescence (C 35 and C 140). PBMCs
were isolated and cryopreserved as described previously (17). Phenotypic
analyses of the sequential PBMC samples were conducted simultaneously
for each individual donor to avoid day-to-day interexperimental varia-
tion. Following thawing and washing in phosphate-buffered saline (PBS),
1,000,000 cells/well were incubated in 96-well v-bottom plates with LIVE/
DEAD-fixable dead-cell Aqua stain (Invitrogen)–PBS for 30 min on ice.
Cells werewashed twicewith staining buffer (PBS containing 0.5%bovine
serum albumin [Sigma]) and stained for 30 min on ice with BDCA-1
(CD1c) fluorescein isothiocyanate (FITC) (AD5 to 8E7), BDCA-2 biotin
(AC144), and BDCA-3 allophycocyanin (AD5 to 14H12) (all Miltenyi)
and with CD16 phycoerythrin (PE) (3G8), CD3 peridinin chlorophyll
protein (PerCP)-Cy5.5 (UCHT1), CD19 PerCP-Cy5.5 (HIB19), CD56
PerCP-Cy5.5 (HCD56), HLA-DR APC-Cy7 (L243), CD14 PeCy7
(HCD14), and CD86 PacBlue (IT2.2) (all BioLegend). Secondary-surface
staining was performed with ECD (Beckman Coulter). Cells were kept in
PBS–1%paraformaldehyde on ice until analyzed. Acquisition of 50,000 to
200,000 events per sample was performed using an ADP 9-color flow
cytometer (Dako/Beckman Coulter). Data were analyzed using FlowJo
v9.6 software. HLA-DR and CD3 CD19 CD56 APCs were subdivided
into classical monocytes (CD14 CD16) and intermediate monocytes
(CD14 CD16) and four CD14 DC subsets based on expression of
CD16 (CD16 mDCs), CD1c (type 1 mDCs or BDCA-1 DCs), BDCA-3
(type 2 mDCs), and BDCA-2 (pDCs) (Fig. 1).
Statistical analysis. Statistical analysis was performed using GraphPad
Prism v5. Cell counts and frequencies and surface marker expression
(geometricmean fluorescence intensity [MFI]) were analyzed by repeated
measures of one-way analysis of variance (ANOVA) with Dunnett’s post
hoc test to compare data from all time points to the C 1 baseline data.
The majority of data were normally distributed as determined by the
D’Agostino-Pearson omnibus normality test. The correlation between
peak parasitemia and immunological outcome was tested using Pearson’s
correlation and log-transferred data for parasitemia. Statistical tests were
performed for volunteers (n  15) at all time points except for the DT
because values were missing for three volunteers at that time point.
Changes on the DT were therefore calculated for only 12 volunteers, but
all other time points were taken into account for themultiple-comparison
corrections.
RESULTS AND DISCUSSION
Upregulation of classical activation markers during CHMI is
restricted to monocytes and CD16 mDCs. During blood-stage
parasitemia, absolute leukocyte and lymphocyte counts (17), as
well as combined monocyte and lymphocyte counts (see Fig. S2A
in the supplemental material), decreased to their nadirs 3 days
after treatment (DT3) (P 0.001). Assessments of APC subset
proportions within the PBMC compartment for the 15 volunteers
who were infected after intradermal injection of P. falciparum
sporozoites (21) showed that no changes in DC and monocyte
frequencies were evident during liver-stage infection and early
blood-stage infection (C 5, C 7, and C 9) (Fig. 2A), except
for a slight increase in the pDC frequency at C 9 (P  0.01).
Upon reaching detectable blood-stage parasitemia and after treat-
ment, monocytes increased in frequency: classical monocytes
peaked on theDT (P 0.001) and intermediatemonocytes onDT
3 (P 0.001). Such transient increases inmonocyte frequencies
during acute infection that resolve after treatment have also been
observed in P. vivax-infected patients (22). While pDC levels re-
mained slightly increased on DT3 (P 0.01), BDCA-3 mDCs
showed a significant decrease in frequency on the DT (P 0.001)
and at DT3 (P 0.01). At C35, monocyte and DC frequen-
cies had recovered to baseline values. The frequency of CD16
mDCs did not change during infection but showed a slight de-
crease on C 35 compared to baseline (P  0.01) which was
recovered onC140. Absolute numbers of classicalmonocytes as
well as of CD1c and BDCA3 mDCs showed a significant drop 3
days after treatment, while the numbers of intermediate mono-
cytes increased and the numbers of CD16 mDCs remained stable
(see Fig. S2B in the supplemental material).
We next assessed the activation status of APCs (Fig. 2B and C).
In both classical and intermediate monocytes, expression of the
peptide antigen-presenting molecule HLA-DR significantly in-
creased during blood-stage infection (P 0.001 at theDT andDT
3) and the costimulatory molecule CD86 was significantly up-
regulated at DT 3 (P  0.001). Activation appeared slightly
stronger in the CD14 CD16 intermediate monocyte subset
than in the classical CD14 CD16 monocytes, which is in line
with a previous study on monocytes in P. vivax infection (22).
Among the DCs, the CD1c, BDCA-2, and BDCA-3 DCs did not
upregulate expression ofHLA-DRorCD86during parasitemia. In
contrast, CD16 mDCs showed a significant increase of HLA-DR
andCD86 expression at DT3 (P 0.01). Of note, we previously
found that, together with classical and intermediate monocytes,
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CD16CD14 inflammatory DCs were also the main BAFF-pro-
ducing APC subset during CHMI, showingmuch stronger induc-
tion of surface BAFF than the only other BAFF-producing DC
subset, namely, classical CD1c mDCs (17). These data are sugges-
tive of a functional distinction betweenCD16mDCs and the other
DC subsets.
Data on inflammatory CD16 mDCs in naturally exposed indi-
viduals are sparse and controversial. Similarly to our findings, a
study in Mali that examined only the proportions of CD16 mDC
found no difference between infected and uninfected individuals
(15). In contrast, a field study in Papuan adults showed a reduc-
tion in absolute numbers of circulating CD16 mDCs in acute P.
falciparum malaria (16). Finally, levels of CD16hi CD14lo mono-
cytes were found to be elevated in malaria-infected compared to
uninfected individuals in aMalawian cohort (23), but it is unclear
how far this subset overlaps the CD14 CD16 intermediate/in-
flammatory monocytes or the CD14 CD16 mDCs examined
here. Whether malaria infection was associated with increased or
decreased phenotypic activation in the different DC subsets de-
pended verymuch on ethnicity in theMalian study. In both ethnic
cohorts, however, CD16mDCs showed reducedHLA-DR expres-
sion. In line with this, HLA-DR expression on CD16 CD14lo
monocytes increased upon curative treatment ofP. vivax infection
(22). On the other hand, CD16 CD14lo monocytes in these P.
vivax-infected patients showed the highest levels of tumor necro-
sis factor alpha (TNF-) and interleukin-6 (IL-6) transcription,
indicating an activated status of these cells (22). Further studies
are needed to resolve these discrepancies, which might also relate
to the degree of parasitemia. Moreover, future studies should in-
vestigate whether these CD16 mDCs might be constituted of
so-called 6-sulfo LacNAc dendritic cells (slanDCs), an inflam-
matory DC type with unique capacities in immune complex-as-
sociated antigen capture, T-cell priming, and antibody-dependent
cellular cytotoxicity (20, 24, 25). These cells are specifically re-
cruited to sites of inflammation (25), which might explain field
findings of reduced circulating CD16 mDC frequencies during
more-prolonged infection in areas of endemicity (16).
Expression of the glycolipid-presenting molecule CD1c on
APC subsets is increased during CHMI. While all four DC sub-
sets were mutually distinct at baseline (Fig. 3A and B and data not
shown), CD1c expression during blood-stage parasitemia was up-
regulated not only in monocytes and CD1c mDCs but also in
CD16 mDC and pDC subsets (Fig. 3A, C, and D) (on the DT,
classical monocytes, P  0.001; intermediate monocytes, P 
0.001; CD16mDCs, P 0.01; CD1cmDCs, P 0.001; and pDCs,
P  0.01; at DT 3; all five subsets, P  0.001). Of note, CD1c
expression in the pDC subsetwas almost absent at baseline and the
increase during infection was only marginal. BDCA-3 mDCs
showed no change in CD1c expression. CD1c expression returned
to baseline values at C 35 for all cell types. Although we found
significant correlations between peak parasitemia and CD1c ex-
pression on several APC subsets on the DT and/or DT3, the R2
FIG 1 Antigen-presenting-cell (APC) gating strategy. (A) Single, viable PBMCs positive for HLA-DR and negative for the lineage markers CD3, CD19, and
CD56. FSC, forward scatter; SSC, side scatter. (B) HLA-DR CD3 CD19 PBMCs were distinguished into CD14 monocytes and CD14 APCs. (C)
Monocytes were subdivided based onCD16 expression intoCD14CD16 classicalmonocytes (I) andCD14CD16 intermediatemonocytes (II). (D)CD14
APCs were gated based on CD16 expression to distinguish CD14 CD16 myeoloid dendritic cells (DCs) (III) (CD16 mDCs). (E) CD14 CD16 APCs were
further subdivided into CD14 CD16 CD1c (IV) (type 1 myeloid DC [CD1c mDCs], also known as BDCA1 mDCs), CD14 CD16 BDCA3 (V) (type 2
mDCs or BDCA3 mDCs), and CD14 CD16 BDCA2 (VI) (plasmacytoid DCs [pDCs]).
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FIG 2 Kinetics of APC subset frequencies and expression of activation markers during and after CHMI. (A) Kinetics of APC subset frequency (percent-
ages of viable PBMCs). (B) Kinetics of HLA-DR expression (geometric mean fluorescence intensity [MFI]) of the six APC subsets. (C) Kinetics of CD86
expression (MFI) of the six APC subsets. Data are presented for each individual donor (gray dots) and as means (n 15) with standard errors of the means
(SEM) (black error bars). *, P 0.05; **, P 0.01; ***, P 0.001 (one-way ANOVA with Dunnett’s post hoc test compared to baseline [C1]). Inclusion
of the outlier (black square) in the CD1c mDC frequency in the statistical analysis renders the increase on the DT significant. C, challenge; DT, day of
treatment.
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was always0.5 (data not shown), indicative of only weak corre-
lations between parasitemia and CD1c expression. Nevertheless,
induction of CD1c expression was clearly linked to exposure to
blood-stage parasites, since no such upregulation was seen in vol-
unteers who remained TS and PCR negative after CHMI (see Fig.
S3A in the supplemental material).
CD1c was originally described as presenting mycobacterial
glycophospholipids (26), synergizes with CD1d in -galacto-
sylceramide presentation to NK-T cells expressing an invariant
T-cell receptor (TCR) (27), and is able to present a diverse
range of ligands to 	T or T cells (28). The latter are acti-
vated and expanded during controlled and natural malaria in-
fection (19, 29), and schizont-stimulated pDCs are able to ac-
tivate T cells (10). The degree to which this expansion and
activation of T cells may be related to altered expression of
CD1c on APCs remains to be investigated. It is further un-
known which glycophospholipids of the malaria parasite or
human erythrocytes are presented by CD1c. However, a subset
of T cells has been identified that recognizes CD1c indepen-
dently of foreign lipid or glycolipid antigens (30). Therefore,
parasite-induced upregulation of CD1c (presenting self-lipids)
might be sufficient to activate T cells without the need for
malaria antigen processing and presentation, circumventing
potential inhibition of this presentation. The early upregula-
tion of CD1c expression might be specifically responsible for
initiating the cascade of the early activation and expansion of
the T-cell compartment and therefore the early production
of gamma interferon (IFN-) (19), leading to further activa-
tion of 	T cells (30) and the induction of memory responses.
We found that the increased expression of CD1c on APCs dur-
ing blood-stage infection is most pronounced on monocytes,
CD16 mDCs, and CD1c mDCs (Fig. 3D and panels I to iv). For
monocytes, this was shown previously in thalassemia B patients
(31). To our knowledge, however, induction of CD1c expression
on CD16 mDCs either during inflammation or in other disease
settings has not been described before. Generally, CD16-positive
blood DCs are described as phenotypically and functionally dis-
tinct and as not overlapping other myeloid blood DCs, based on
detailed analysis in noninflammatory circumstances (2–4). One
study in healthy individuals, however, described a subset of DC-
specific intercellular adhesion molecule-3-grabbing nonintegrin
(DC-SIGN)-expressing DCs, 50% of which also expressed CD16
as well as low levels of CD1c (32). Other studies exploring DC
populations in healthy volunteers or during in vivo infection or
inflammation determined only CD1c and CD16 expression in
separated gating strategies (15, 33). In bacteriologically confirmed
TB patients, no upregulation of CD1c in CD14 CD16 cells oc-
curred (34). Whether the upregulation of CD1c in CD16mDCs is
malaria specific or rather a general feature of activation of CD16
mDCs in certain infections remains to be investigated.
APC subsets show temporarily increased expression of
FcIII receptor CD16 during CHMI.Not only CD1c but also the
FcIII receptor CD16 was significantly upregulated on classical
and intermediate monocytes as well as CD16 mDCs during peak
activation (Fig. 3E and F). Again, no such upregulationwas seen in
volunteers who remained TS and PCR negative after CHMI (see
Fig. S3B in the supplemental material). CD1cmDCs (Fig. 3B) and
BDCA-2 pDCs (data not shown), defined as CD16 negative at
baseline, also showed upregulation of CD16, albeit only verymar-
ginal upregulation, and therefore did not merge into the CD16
DC subset. Whether this only very slight induction of CD16 ex-
pression on CD1c mDCs and pDCs can have any functional rele-
vance remains to be determined. CD16 binds immune complexes,
and the binding triggers effector functions such as phagocytosis
and proinflammatory cytokine secretion (35). Immune com-
plexes are formed particularly during episodes of severemalaria, a
condition associated with higher frequencies of CD16 mono-
cytes (36). Moreover, following malaria infection, elevated CD16
expression on monocytes is associated with enhanced TNF pro-
duction, as well as with a reduced hemoglobin level (36). This
suggests that CD16 cross-linking by malaria-induced immune
complexes can trigger inflammatory responses and erythrophago-
cytosis. Our findings warrant future studies into the effect of tem-
porarily increased CD16 expression, particularly on monocytes
and inflammatory CD16 mDCs, even during uncomplicated,
early malaria infection, on downstream immune responses. In-
creased capture of immune complex-associated antigens might,
for instance, enhance antigen presentation (20). The recovery of
baseline CD16 expression levels on APCs after convalescence ob-
served after CHMI would be consistent with shedding of CD16
upon maturation, as shown for CD16 slanDCs (25).
Finally, our findings highlight the importance of careful phe-
notypic analysis of DC subsets in circumstances of immune acti-
vation. CD16 and CD1c define two functionally separate sub-
classes of DCs that are phenotypically distinct under steady-state
conditions (2, 3).When cells are activated, however, bothmarkers
can be upregulated on both subsets. Classification of activated
DCs as defined under noninflammatory circumstances may
therefore lead tomisinterpretation of the results of direct compar-
isons of noninflammatory and inflammatory time points. The
strong upregulation of CD1c expression, particularly on CD16
mDCs, the only DC subset showing activation marker expression
during CHMI, highlights the need to include CD16 as a marker in
assessing differentDC subsets during immune activation, to avoid
assigning phenotypic changes or functional features to the wrong
DC subset.
Concluding remarks. In conclusion, we show that monocytes
and inflammatory CD16 mDCs are activated upon exposure to
the blood-stage malaria parasite and that these APCs upregulate
expression of CD16 and CD1c upon malaria infection in vivo.
These data warrant future studies to examine whether potentially
increased antigen capture inmonocytes and a specializedDC sub-
set, as well as enhanced glycolipid antigen presentation in addition
FIG 3 CD1c andCD16 expression onAPCs during CHMI. (A and B) Representative plots showing CD1c andCD16 expression onCD16mDCs (black dots) (A)
or CD1c mDCs (black dots) (B) at baseline (C1) and peak activation (DT3). Gray dots in panels A and B show all DCs. (C) Expression of CD1c on APC
subsets. (D) Expression (geometric mean fluorescence intensity [MFI]) of CD1c on APC subsets over time. (E) CD16 expression on APC subsets. (F) Expression
(MFI) of CD16 on APC subsets over time. Panels C and E show representative histogram plots from one donor at baseline (gray) and DT3 (bold line). Data
in panels D and F are presented for each individual donor (gray dots) and asmeans (n 15) with SEM (black error bars).*, P 0.05; **, P 0.01; ***, P 0.001
(one-way ANOVA with Dunnett’s post hoc test compared to baseline [C1]). C, challenge; DT, day of treatment.
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to the classical MHC-II peptide presentation, might contribute to
the initiation of T-cell responses in malaria.
ACKNOWLEDGMENTS
We thank the trial volunteers and the staff from the Clinical Research
Centre Nijmegen, the Radboud University Medical Center, and the
Sanaria Manufacturing Team, all of whom made this study possible. We
thank Rob Hermsen for performing the quantitative PCR analysis.
This work was supported by Top Institute Pharma (Grant T4-102)
and the FP7-founded European Virtual Institute of Malaria Research
(Grant 242095). A.C.T. received a European Vaccine Initiative EMVDA
Ph.D. scholarship. A.S. received an EMBO long-termpostdoctoral fellow-
ship. Development andmanufacturing of PfSPZChallenge was supported
by SIBR grants R44AI058375-03, -04, -05, and -05S1 from the NIAID/
NIH and grant 07984 (PATHMalaria Vaccine Initiative, with funds from
the Bill and Melinda Gates Foundation).
A.C.T. and A.S. conducted experiments; A.C.T. designed experiments
and analyzed data; M.R. and E.M.B. performed the clinical study and
collected clinical data; S.L.H. contributed vital reagents; A.C.T, R.W.S.,
andA.S. interpreted the data andwrote themanuscript; andM.R., E.M.B.,
and S.L.H. critically revised the manuscript.
S.L.H. is Chief Executive and Scientific Officer at Sanaria Inc., which
manufactured PfSPZ Challenge, and thus does have a potential conflict of
interest. The other authors declare no commercial or financial conflict of
interest.
REFERENCES
1. WHO. 2013. World malaria report: 2013. World Health Organization,
Geneva, Switzerland.
2. Piccioli D, Tavarini S, Borgogni E, Steri V, Nuti S, Sammicheli C, Bardelli
M, Montagna D, Locatelli F, Wack A. 2007. Functional specialization of
human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood
109:5371–5379. http://dx.doi.org/10.1182/blood-2006-08-038422.
3. MacDonald KP, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DN.
2002. Characterization of human blood dendritic cell subsets. Blood 100:
4512–4520. http://dx.doi.org/10.1182/blood-2001-11-0097.
4. Lindstedt M, Lundberg K, Borrebaeck CA. 2005. Gene family clustering
identifies functionally associated subsets of human in vivo blood and ton-
sillar dendritic cells. J Immunol 175:4839–4846. http://dx.doi.org/10
.4049/jimmunol.175.8.4839.
5. Wykes MN, Good MF. 2008. What really happens to dendritic cells
during malaria? Nat Rev Microbiol 6:864–870.
6. Scholzen A, Minigo G, Plebanski M. 2010. Heroes or villains? T regula-
tory cells in malaria infection. Trends Parasitol 26:16–25. http://dx.doi
.org/10.1016/j.pt.2009.10.004.
7. Urban BC, Cordery D, Shafi MJ, Bull PC, Newbold CI, Williams TN,
Marsh K. 2006. The frequency of BDCA3-positive dendritic cells is increased
in the peripheral circulation of Kenyan children with severe malaria. Infect
Immun 74:6700–6706. http://dx.doi.org/10.1128/IAI.00861-06.
8. Woodberry T, Minigo G, Piera KA, Amante FH, Pinzon-Charry A,
Good MF, Lopez JA, Engwerda CR, McCarthy JS, Anstey NM. 2012.
Low-level Plasmodium falciparum blood-stage infection causes dendritic
cell apoptosis and dysfunction in healthy volunteers. J Infect Dis 206:333–
340. http://dx.doi.org/10.1093/infdis/jis366.
9. Urban BC, Mwangi T, Ross A, Kinyanjui S, Mosobo M, Kai O, Lowe B,
Marsh K, Roberts DJ. 2001. Peripheral blood dendritic cells in children
with acute Plasmodium falciparum malaria. Blood 98:2859–2861. http:
//dx.doi.org/10.1182/blood.V98.9.2859.
10. Pichyangkul S, Yongvanitchit K, Kum-arb U, Hemmi H, Akira S, Krieg
AM, Heppner DG, Stewart VA, Hasegawa H, Looareesuwan S, Shanks
GD, Miller RS. 2004. Malaria blood stage parasites activate human plas-
macytoid dendritic cells and murine dendritic cells through a Toll-like
receptor 9-dependent pathway. J Immunol 172:4926–4933. http://dx.doi
.org/10.4049/jimmunol.172.8.4926.
11. Elliott SR, Spurck TP, Dodin JM, Maier AG, Voss TS, Yosaatmadja F,
Payne PD, McFadden GI, Cowman AF, Rogerson SJ, Schofield L,
Brown GV. 2007. Inhibition of dendritic cell maturation by malaria is
dose dependent and does not require Plasmodium falciparum erythrocyte
membrane protein 1. Infect Immun 75:3621–3632. http://dx.doi.org/10
.1128/IAI.00095-07.
12. Wilson NS, Behrens GM, Lundie RJ, Smith CM, Waithman J, Young L,
Forehan SP, Mount A, Steptoe RJ, Shortman KD, de Koning-Ward TF,
Belz GT, Carbone FR, Crabb BS, Heath WR, Villadangos JA. 2006.
Systemic activation of dendritic cells by Toll-like receptor ligands or ma-
laria infection impairs cross-presentation and antiviral immunity. Nat
Immunol 7:165–172. http://dx.doi.org/10.1038/ni1300.
13. Millington OR, Gibson VB, Rush CM, Zinselmeyer BH, Phillips RS,
Garside P, Brewer JM. 2007. Malaria impairs T cell clustering and im-
mune priming despite normal signal 1 from dendritic cells. PLoS Pathog
3:1380–1387.
14. Urban BC, Ferguson DJ, Pain A, Willcox N, Plebanski M, Austyn JM,
Roberts DJ. 1999. Plasmodium falciparum-infected erythrocytes modu-
late the maturation of dendritic cells. Nature 400:73–77. http://dx.doi.org
/10.1038/21900.
15. Arama C, Giusti P, Bostrom S, Dara V, Traore B, Dolo A, Doumbo O,
Varani S, Troye-Blomberg M. 2011. Interethnic differences in antigen-
presenting cell activation and TLR responses in Malian children during
Plasmodium falciparum malaria. PLoS One 6:e18319. http://dx.doi.org
/10.1371/journal.pone.0018319.
16. Pinzon-Charry A, Woodberry T, Kienzle V, McPhun V, Minigo G,
Lampah DA, Kenangalem E, Engwerda C, Lopez JA, Anstey NM, Good
MF. 8 July 2013, posting date. Apoptosis and dysfunction of blood den-
dritic cells in patients with falciparum and vivax malaria. J Exp Med http:
//dx.doi.org/10.1084/jem.20121972.
17. Scholzen A, Teirlinck AC, Bijker EM, Roestenberg M, Hermsen CC,
Hoffman SL, Sauerwein RW. 19 March 2014, posting date. BAFF and
BAFF receptor levels correlate with B cell subset activation and redistribu-
tion in controlled human malaria infection. J Immunol http://dx.doi.org
/10.4049/jimmunol.1302960.
18. Cohen NR, Garg S, Brenner MB. 2009. Antigen presentation by CD1
lipids, T cells, and NKT cells in microbial immunity. Adv Immunol 102:
1–94. http://dx.doi.org/10.1016/S0065-2776(09)01201-2.
19. Inoue SI, Niikura M, Mineo S, Kobayashi F. 2013. Roles of IFN-gamma
and gammadelta T cells in protective immunity against blood-stage ma-
laria. Front Immunol 4:258.
20. Döbel T, Kunze A, Babatz J, Tränkner K, Ludwig A, Schmitz M, Enk A,
Schäkel K. 2013. FcgammaRIII (CD16) equips immature 6-sulfo LacNAc-
expressing dendritic cells (slanDCs) with a unique capacity to handle IgG-
complexed antigens. Blood 121:3609–3618. http://dx.doi.org/10.1182/blood
-2012-08-447045.
21. Roestenberg M, Bijker EM, Sim BK, Billingsley PF, James ER, Bastiaens
GJ, Teirlinck AC, Scholzen A, Teelen K, Arens T, van der Ven AJ,
Gunasekera A, Chakravarty S, Velmurugan S, Hermsen CC, Sauerwein
RW, Hoffman SL. 13 November 2012, posting date. Controlled human
malaria infections by intradermal injection of cryopreserved Plasmodium
falciparum sporozoites. Am J Trop Med Hyg http://dx.doi.org/10.4269
/ajtmh.2012.12-0613.
22. Antonelli LR, Leoratti FM, Costa PA, Rocha BC, Diniz SQ, Tada MS,
Pereira DB, Teixeira-Carvalho A, Golenbock DT, Goncalves R,
Gazzinelli RT. 2014. The CD14 CD16 inflammatory monocyte subset
displays increased mitochondrial activity and effector function during
acute Plasmodium vivaxmalaria. PLoS Pathog 10:e1004393. http://dx.doi
.org/10.1371/journal.ppat.1004393.
23. Jaworowski A, Kamwendo DD, Ellery P, Sonza S, Mwapasa V, Tadesse
E, Molyneux ME, Rogerson SJ, Meshnick SR, Crowe SM. 2007. CD16
monocyte subset preferentially harbors HIV-1 and is expanded in preg-
nant Malawian women with Plasmodium falciparum malaria and HIV-1
infection. J Infect Dis 196:38–42. http://dx.doi.org/10.1086/518443.
24. Schmitz M, Zhao S, Schakel K, Bornhauser M, Ockert D, Rieber EP.
2002. Native human blood dendritic cells as potent effectors in antibody-
dependent cellular cytotoxicity. Blood 100:1502–1504.
25. Schäkel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, Soruri
A, von Kietzell M, Rieber E. 2002. 6-Sulfo LacNAc, a novel carbohydrate
modification of PSGL-1, defines an inflammatory type of human den-
dritic cells. Immunity 17:289–301. http://dx.doi.org/10.1016/S1074-7613
(02)00393-X.
26. Brigl M, Brenner MB. 2004. CD1: antigen presentation and T cell func-
tion. AnnuRev Immunol 22:817–890. http://dx.doi.org/10.1146/annurev
.immunol.22.012703.104608.
27. Fox LM, Miksanek J, May NA, Scharf L, Lockridge JL, Veerapen N,
Besra GS, Adams EJ, Hudson AW, Gumperz JE. 2013. Expression of
CD1c enhances human invariant NKT cell activation by alpha-GalCer.
Teirlinck et al.
3738 iai.asm.org September 2015 Volume 83 Number 9Infection and Immunity
 o
n
 February 28, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://iai.asm
.org/
D
ow
nloaded from
 
Cancer Immun 13:9.
28. Adams EJ. 2013. Diverse antigen presentation by the group 1 CD1molecule,
CD1c. Mol Immunol 55:182–185. http://dx.doi.org/10.1016/j.molimm.2012
.10.019.
29. Teirlinck AC, McCall MB, Roestenberg M, Scholzen A, Woestenenk R,
de Mast Q, van der Ven AJ, Hermsen CC, Luty AJ, Sauerwein RW.
2011. Longevity and composition of cellular immune responses following
experimental Plasmodium falciparummalaria infection in humans. PLoS
Pathog 7:e1002389. http://dx.doi.org/10.1371/journal.ppat.1002389.
30. Spada FM, Grant EP, Peters PJ, Sugita M, Melian A, Leslie DS, Lee HK,
van Donselaar E, Hanson DA, Krensky AM, Majdic O, Porcelli SA,
Morita CT, Brenner MB. 2000. Self-recognition of CD1 by gamma/delta
T cells: implications for innate immunity. J Exp Med 191:937–948. http:
//dx.doi.org/10.1084/jem.191.6.937.
31. Sloma I, Zilber MT, Charron D, Girot R, Tamouza R, Gelin C. 2004.
Upregulation and atypical expression of the CD1molecules onmonocytes
in sickle cell disease. Hum Immunol 65:1370–1376. http://dx.doi.org/10
.1016/j.humimm.2004.09.009.
32. Engering A, Van Vliet SJ, Geijtenbeek TB, Van Kooyk Y. 2002. Subset of
DC-SIGN() dendritic cells in human blood transmits HIV-1 to T lympho-
cytes. Blood 100:1780–1786. http://dx.doi.org/10.1182/blood-2001-12-0179.
33. Mittag D, Proietto AI, Loudovaris T, Mannering SI, Vremec D, Short-
man K, Wu L, Harrison LC. 2011. Human dendritic cell subsets from
spleen and blood are similar in phenotype and function but modified by
donor health status. J Immunol 186:6207–6217. http://dx.doi.org/10
.4049/jimmunol.1002632.
34. Castano D, Garcia LF, Rojas M. 2011. Increased frequency and cell death of
CD16monocyteswithMycobacterium tuberculosis infection. Tuberculosis
(Edinb) 91:348–360. http://dx.doi.org/10.1016/j.tube.2011.04.002.
35. Ravetch JV, Bolland S. 2001. IgG Fc receptors. Annu Rev Immunol
19:275–290. http://dx.doi.org/10.1146/annurev.immunol.19.1.275.
36. Ogonda LA, Orago AS, Otieno MF, Adhiambo C, Otieno W, Stoute JA.
2010. The levels of CD16/Fc gamma receptor IIIA on CD14 CD16
monocytes are higher in children with severe Plasmodium falciparum
anemia than in children with cerebral or uncomplicated malaria. Infect
Immun 78:2173–2181. http://dx.doi.org/10.1128/IAI.01078-09.
Antigen-Presenting Cell Activation during Malaria
September 2015 Volume 83 Number 9 iai.asm.org 3739Infection and Immunity
 o
n
 February 28, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://iai.asm
.org/
D
ow
nloaded from
 
